PMID- 31356562 OWN - NLM STAT- MEDLINE DCOM- 20200922 LR - 20211204 IS - 1728-7731 (Electronic) IS - 1726-4901 (Linking) VI - 82 IP - 9 DP - 2019 Sep TI - Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. PG - 693-698 LID - 10.1097/JCMA.0000000000000148 [doi] AB - BACKGROUND: Based on the previously published results, 12 weeks of sofosbuvir (SOF) 400 mg/day plus ribavirin (RBV), the current direct antiviral agent regimen reimbursed by Bureau-of National-Health-Insurance (BNHI) of Taiwan for genotype-2 chronic hepatitis C (CHC), is suboptimal in efficacy, especially for difficult-to-treat subpopulations such as liver cirrhosis, previous interferon (IFN) treatment failure, and high viral-load. This study aimed to evaluate the efficacy and safety of SOF plus daclatasvir (DCV) for Taiwanese genotype-2 CHC patients. METHODS: Between March 2017 and December 2018, a total of 50 consecutive genotype-2 CHC patients who completed 12 weeks combination of SOF (400 mg/day) plus DCV (60 mg/day) with or without RBV by investigators were enrolled for analyses. When RBV was added, weight-based (800-1200 mg/day) approach was applied. Sustained virological response (SVR12) was defined by undetectable HCV RNA (<15 IU/mL) at the end and 12 weeks after completion of therapy. RESULTS: The mean age was 62.0 +/- 11.4 years, 16 (32.0%) of them were males and 20 (40.0%) of them failed to previous IFN. Severity of liver diseases was as follows: /= 2 million IU/mL. The rates of undetectable HCV RNA (<15 IU/mL) at weeks 2, 4, and end-of-treatment were 40%, 94%, and 100%, respectively. Majority (66.7%) of patients with detectable HCV RNA at week 2 belonged to low-level viremia (<50 IU/mL). Subjective adverse events (AEs) and laboratory abnormalities were more common for patients combining RBV. Grades of AEs were generally mild and all patients finished therapy without interruption. After post-treatment follow-up, all 50 patients (100%) achieved SVR12. CONCLUSION: Our real-world cohort of Taiwan showed that a 12-week SOF/DCV-based treatment was well-tolerated and highly effective for genotype-2 CHC patients with or without liver cirrhosis. FAU - Wu, Sih-Hsien AU - Wu SH AD - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. FAU - Chu, Chi-Jen AU - Chu CJ AD - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. FAU - Su, Chien-Wei AU - Su CW AD - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. FAU - Lin, Chung-Chi AU - Lin CC AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. AD - Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. FAU - Lee, Shou-Dong AU - Lee SD AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. AD - Division of Gastroenterology, Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, ROC. FAU - Wang, Yuan-Jen AU - Wang YJ AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. AD - Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. FAU - Lee, Fa-Yauh AU - Lee FY AD - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. FAU - Huang, Yi-Hsiang AU - Huang YH AD - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. FAU - Hou, Ming-Chih AU - Hou MC AD - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. AD - Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC. LA - eng PT - Journal Article PL - Netherlands TA - J Chin Med Assoc JT - Journal of the Chinese Medical Association : JCMA JID - 101174817 RN - 0 (Antiviral Agents) RN - 0 (Carbamates) RN - 0 (Imidazoles) RN - 0 (Pyrrolidines) RN - 0 (RNA, Viral) RN - 49717AWG6K (Ribavirin) RN - HG18B9YRS7 (Valine) RN - LI2427F9CI (daclatasvir) RN - WJ6CA3ZU8B (Sofosbuvir) SB - IM MH - Adult MH - Aged MH - Antiviral Agents/*administration & dosage MH - Carbamates MH - Drug Therapy, Combination MH - Female MH - Genotype MH - Hepacivirus/classification MH - Hepatitis C, Chronic/*drug therapy/virology MH - Humans MH - Imidazoles/*administration & dosage/adverse effects MH - Male MH - Middle Aged MH - Pyrrolidines MH - RNA, Viral/blood MH - Retrospective Studies MH - Ribavirin/*administration & dosage/adverse effects MH - Sofosbuvir/*administration & dosage/adverse effects MH - Valine/analogs & derivatives EDAT- 2019/07/30 06:00 MHDA- 2020/09/23 06:00 CRDT- 2019/07/30 06:00 PHST- 2019/07/30 06:00 [pubmed] PHST- 2020/09/23 06:00 [medline] PHST- 2019/07/30 06:00 [entrez] AID - 10.1097/JCMA.0000000000000148 [doi] PST - ppublish SO - J Chin Med Assoc. 2019 Sep;82(9):693-698. doi: 10.1097/JCMA.0000000000000148.